We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+20.28%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$14.6M
Cap. Flow
+$2.27M
Cap. Flow %
1.69%
Top 10 Hldgs %
93.35%
Holding
19
New
2
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CASC
Cascadian Therapeutics, Inc.
CASC
+$3.89M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.16M
3
IMDZ
Immune Design Corp.
IMDZ
+$896K

Top Sells

Rank Stock Value
1
NOVN
Novan, Inc. Common Stock
NOVN
+$1.53M
2
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
+$1.17M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$973K

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.74B
$56.6M 42.2%
2,601,814
– –
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$25.1M 18.67%
1,301,413
– –
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$18.4M 13.75%
219,901
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$6.86M 5.11%
1,600,000
– –
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.83M 2.85%
+925,000
New +$3.89M
CHMA
6
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.54M 2.64%
2,080,595
– –
TARA icon
7
Protara Therapeutics
TARA
$230M
$3.43M 2.56%
50,447
– –
EVAR
8
DELISTED
Lombard Medical, Inc.
EVAR
$2.71M 2.02%
3,473,452
– –
CLLS
9
Cellectis
CLLS
$271M
$2.4M 1.79%
100,000
– –
DERM
10
DELISTED
Dermira, Inc.
DERM
$2.39M 1.78%
70,000
– –
IMDZ
11
DELISTED
Immune Design Corp.
IMDZ
$2.38M 1.77%
352,300
+155,000
+79% +$896K
AUPH icon
12
Aurinia Pharmaceuticals
AUPH
$2.01B
$1.85M 1.38%
+252,129
New +$1.16M
OCGN icon
13
Ocugen
OCGN
$440M
$1.48M 1.1%
14,815
– –
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$1.38M 1.02%
250,000
– –
SENS icon
15
Senseonics Holdings Inc
SENS
$263M
$920K 0.69%
25,844
– –
INNL
16
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$586K 0.44%
537,235
– –
NOVN
17
DELISTED
Novan, Inc. Common Stock
NOVN
$337K 0.25%
5,337
-14,663
-73% -$1.53M
DRNA
18
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-337,825
Closed -$973K
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-107,715
Closed -$1.17M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2017 Portfolio in Review

As of Q1 2017, Abingworth held 19 positions worth $134M, up 12% from $120M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Abingworth's Q1 2017 filing shows 2 new, 1 increased, 1 reduced and 2 closed positions. Its largest new stake was Cascadian Therapeutics, Inc.: 925,000 shares worth $3.83M. The largest sale was Novan, Inc. Common Stock, an estimated $1.53M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

  • Abingworth's largest Q1 2017 buy was Cascadian Therapeutics, Inc.: 925,000 shares worth $3.83M.
  • Abingworth added most to Immune Design Corp. in Q1 2017, an estimated $896K increase.
  • Abingworth's biggest Q1 2017 reduction was Novan, Inc. Common Stock, cutting an estimated $1.53M.
  • Abingworth fully exited Anthera Pharmaceuticals, Inc. in Q1 2017, selling an estimated $1.17M.
  • Abingworth's ten largest holdings make up 93% of its $134M portfolio in Q1 2017.
  • Abingworth opened 2 new positions and closed 2 in Q1 2017.
  • Abingworth's portfolio value rose 12% quarter-over-quarter to $134M.

Based on Abingworth's 13F filing for Q1 2017, filed 15 May 2017.